Our Pipeline

CT-388 is an investigational once-weekly, injectable, dual GLP-1/GIP receptor modulator being studied in a multi-part, multi-cohort Phase 1/2 trial to assess its safety, tolerability, pharmacokinetics and pharmacodynamic effects vs. placebo in overweight and obese heathy volunteers as well as in a cohort of overweight and obese participants with type 2 diabetes. Further details about the trial can be found at https://clinicaltrials.gov/ct2/show/NCT04838405.

CT-868 is an investigational once-daily, injectable dual GLP-1/GIP receptor modulator being studied in two trials:

• CT-868-002: A Phase 2 global multi-center double blind, randomized placebo-controlled dose-ranging trial assessing efficacy and safety over 26 weeks in overweight and obese participants with type 2 diabetes.
• CT-868-005: A randomized, double-blind, placebo and comparator-controlled crossover study to assess the effects of CT-868 treatment on glucose homeostasis in participants with type 1 diabetes. Further details about the trial can be found at https://clinicaltrials.gov/ct2/show/NCT05794581.

CT-996 is an investigational once-daily, oral, small molecule GLP-1 receptor agonist) being studied in a Phase 1 clinical trial to assess its safety, tolerability, pharmacokinetic and pharmacodynamic effects in overweight/obese adults with and without type 2 diabetes.